Pfizer signs deal with Allogene to develop cancer cell therapy
The agreement will accelerate the development of Pfizer's chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy for treating cancer.
Tuesday, April 3, 2018
Pfizer signs deal with Allogene to develop cancer cell therapy
Pfizer signs deal with Allogene to develop cancer cell therapy
The agreement will accelerate the development of Pfizer's chimeric antigen receptor T cell (CAR T) therapy, an investigational immune cell therapy for treating cancer.
Related Posts:
0 comments:
Post a Comment